Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2

S Sonam Puri N Nofisat Ismaila (American Society of Clinical Oncology (ASCO), Alexandria, VA, US) I Ibrahim Hanna Azar (IHA Hematology Oncology Consultants, Ypsilanti, MI) J Janet Freeman-Daily (The ROS1ders, Seattle, WA) N Naoki Furuya (St Marianna University School of Medicine, Kawasaki, Japan) S Sara Kuruvilla (London Health Sciences Centre, London, ON, Canada) L Logan Roof (Ohio State University, Columbus, OH) A Ana I. Velazquez Y Yubao Wang (Department of Cancer Biology, Dana-Farber Cancer Institute) P Paul Wheatley Price (The Ottawa Hospital Research Institute/University of Ottawa, Ottawa, ON, Canada) N Natasha B. Leighl

Abstract

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found on the ASCO Publications website .

Article Details

Volume / Issue Vol. 1, Issue 1
Published June 29, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

S

Sonam Puri

N

Nofisat Ismaila

American Society of Clinical Oncology (ASCO), Alexandria, VA, US

I

Ibrahim Hanna Azar

IHA Hematology Oncology Consultants, Ypsilanti, MI

J

Janet Freeman-Daily

The ROS1ders, Seattle, WA

N

Naoki Furuya

St Marianna University School of Medicine, Kawasaki, Japan

S

Sara Kuruvilla

London Health Sciences Centre, London, ON, Canada

L

Logan Roof

Ohio State University, Columbus, OH

A

Ana I. Velazquez

Y

Yubao Wang

Department of Cancer Biology, Dana-Farber Cancer Institute

P

Paul Wheatley Price

The Ottawa Hospital Research Institute/University of Ottawa, Ottawa, ON, Canada

N

Natasha B. Leighl